Infusion Center Locator

Search for infusion centers near you by entering your city or ZIP Code or click below to request inclusion of your facility.

      Important Safety Information Expand

      WARNING: ANAPHYLAXIS

      • Anaphylaxis has been observed with PEMGARDA in 0.6% (4/623) of participants in a clinical trial.
      • Anaphylaxis was reported during the first and second infusion of PEMGARDA.
      • Anaphylaxis can be life-threatening.
      • Prior to administering PEMGARDA, consider the potential benefit of COVID-19 prevention along with the risk of anaphylaxis.
      • Administer PEMGARDA only in settings in which healthcare providers have immediate access to medications to treat anaphylaxis and the ability to activate the emergency medical system (EMS), as necessary.
      • Clinically monitor individuals during the infusion and for at least two hours after completion of the infusion.
      • Discontinue PEMGARDA immediately if signs or symptoms of anaphylaxis or any severe systemic reaction are observed and initiate appropriate medications and/or supportive therapy.

      CONTRAINDICATIONS

      PEMGARDA is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of PEMGARDA.

      WARNINGS AND PRECAUTIONS

      Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

      Serious hypersensitivity reactions, including anaphylaxis, have been observed with PEMGARDA. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration, and initiate appropriate medications and/or supportive therapy. Clinically monitor individuals during infusion and observe for at least two hours after infusion is complete.

      Risk of Cross-Hypersensitivity With COVID-19 Vaccine

      PEMGARDA contains polysorbate 80, which is in some COVID-19 vaccines and is structurally similar to polyethylene glycol (PEG), an ingredient in other COVID-19 vaccines. For individuals with a history of severe hypersensitivity reaction to a COVID-19 vaccine, consider consultation with an allergist-immunologist prior to PEMGARDA administration.

      Risk for COVID-19 Due to SARS-CoV-2 Viral Variants with Substantially Reduced Susceptibility to PEMGARDA

      Certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA. PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. Inform individuals of the increased risk, compared to other variants, for COVID-19 due to SARS-CoV-2 viral variants that exhibit significantly reduced susceptibility to PEMGARDA. If signs and symptoms of COVID-19 occur, advise individuals to test for COVID-19 and seek medical attention, including starting treatment for COVID-19 as appropriate.

      ADVERSE REACTIONS

      The most common adverse events (all grades, incidence ≥2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea.

      USE IN SPECIFIC POPULATIONS

      Pregnancy

      There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. PEMGARDA should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

      Lactation

      There are no available data on the presence of PEMGARDA in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PEMGARDA and any potential adverse effects on the breastfed infant from PEMGARDA.

      Pediatric Use

      PEMGARDA is not authorized for use in pediatrics less than 12 years of age or weighing less than 40 kg. The safety and effectiveness of PEMGARDA has not been established in pediatrics.

      See full Fact Sheet for Healthcare Providers and Fact Sheet for Patients, Parents, and Caregivers for examples of medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination, the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19. The FDA Letter of Authorization is also available for reference.

      The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory reporting of all serious adverse events* and medication errors potentially related to PEMGARDA within 7 calendar days from the healthcare provider’s awareness of the event, using FDA Form 3500 (for information on how to access this form, see below). The FDA requires that such reports, using FDA Form 3500, include the following:

      • Patient demographics and baseline characteristics (e.g., patient identifier, age or date of birth, sex, weight, ethnicity, and race).
      • A statement “PEMGARDA use for the pre-exposure prophylaxis of COVID-19 under Emergency Use Authorization (EUA)” under the “Describe Event, Problem, or Product Use/Medication Error” heading.
      • Information about the serious adverse event or medication error (e.g., signs and symptoms, test/laboratory data, complications, timing of drug initiation in relation to the occurrence of the event, duration of the event, treatment required to mitigate the event, evidence of event improvement/disappearance after stopping or reducing the dosage, evidence of event reappearance after reintroduction, clinical outcomes).
      • Patient’s preexisting medical conditions and use of concomitant products.
      • Information about the product (e.g., dosage, route of administration, NDC #).

      Submit serious adverse event and medication error reports using FDA Form 3500 to FDA MedWatch using one of the following methods:

      • Complete and submit the report online: www.fda.gov/medwatch/report.htm
      • Complete and submit a postage-paid FDA Form 3500 and return by:
        • Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
        • Fax to 1-800-FDA (332)-0178, or
      • Call 1-800-FDA (332)-1088 to request a reporting form.

      In addition, please provide a copy of all FDA MedWatch forms to:

      Invivyd, Inc.
      Email: pv@invivyd.com
      Or call Invivyd, Inc. at 1-800-890-3385 to report serious adverse events.

      The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory responses to requests from FDA for information about serious adverse events and medication errors following receipt of PEMGARDA.

      *Serious adverse events are defined as:

      • Death
      • A life-threatening adverse event
      • Inpatient hospitalization or prolongation of existing hospitalization
      • A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
      • A congenital anomaly/birth defect
      • Other important medical events, which may require a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly

      You may report side effects related to Invivyd, Inc. products by sending an email to medinfo@invivyd.com.